Neuroplasticity is pointed to the ability of the brain to change its molecular and structural characteristics that hinder its function. The main pathophysiological alteration in schizophrenic patients is the occurrence of a major deficit in cognitive process that are under the control of the circuitry of the dorsolateral prefrontal cortex (DLPFC) (White, 1989 and Hayley and Litteljohn, 2013). Additionally, this cognitive deficit in schizophrenia is partially related to the marked decrease in dopamine [DA] input to the DLPFC. However and fortunately, a compensatory response in the form of up-regulation of D1 receptor in this area of brain results in a great improvement of memory-related DLPFC activity.

Studies performed by Elvevag and Goldberg, 2000 and Black et al, 2004 assumed that schizophrenic patients suffered from brain atrophy, neurotoxicity, or neurodegeneration that involved loss of neurons in the gray matter. Additionally, the reduction in brain volume was due to shrinkage of the neuropil surrounding the neurons with marked reduction in dendrite length that was associated with a reduction in the number and size of dendritic extensions.
This disorder is related to an alteration in the functional activity of the dorsolateral prefrontal cortex (DLPFC). DLPFC is a brain region that is related to the control of executive function. Any abnormalities in the function of DLPFC is strongly related to the development and progress of schizophrenic symptoms (Callicott et al, 2003).

Every dendritic spine of neurons of DLPFC is composed of an excitatory synapse due to the presence of the excitatory amino acid mediator, glutamate. When neurodegenerative changes start in this area of brain, it is associated with a decrease in neurotropin 3 (NT-3, as a brain growth factor) causing a brain tissue loss during schizophrenia together with a decline in growth factors that are critical in brain development, neuroplasticity, and synaptic connectivity (Shoval & Weizman, 2005 and Arellano et al, 2007). On the other hand, it was proved that the pathological alteration in the density of lamina of each spine played a crucial role in the development of schizophrenia.

No animal study has found any effect of first generation antipsychotics (FGAs) e.g. Haloperidol on neurogenesis or neuroplasticity as proved by Wakade et al, (2002). Furthermore, it was found that haloperidol possesses a neurotoxic action on DLPFC by apoptotic cell death with a reduction in neurotropins, such as brain-derived neurotropic factor (BDNF) as brain growth factors. Approximately, no human study was interested to do further investigations by this generation in schizophrenia (Ukai et al, 2004 and Wei et al, 2006).

In contrary to FGAs, many second generation antipsychotics (SGAs) stimulate neurogenesis in the adult rat’ brain especially hippocampus and DLPFC (Wakade et al, 2002 and Leung et al, 2011).

Fortunately, in repeated restrained rats with psychotic manifestations, quetiapine, risperidone and Paliperidone, an SGA and the active metabolite of risperidone and is now approved for the treatment of schizophrenia, were found to
be able to stimulate neurogenesis in hippocampus and other brain areas related to memory maintenance in these experimental rats (Luo et al, 2005 and Nasrallah & Pixley, 2006).

Hippocampal neuroplasticity is dependent on neurotropins as nerve growth factor (NGF) and BDNF to help maintenance of memory and cognitive functions in elderly (Pillai et al, 2006 and Parich et al, 2004). Meanwhile, a marked hyperplasia of the striatum is found to be associated with changes in the morphology and the number of synapses, mainly of the glutamatergic type (Konradi et al, 2001 and Doan et al, 2015). The above findings support the assumption that SGAs also improve neuroplasticity in brain regions whose damage is responsible for the pathogenesis of schizophrenia such as the prefrontal and limbic areas. There is a strong evidence that SGAs increase the neuronal growth factor “neurotropin-3” in the cortex of people with schizophrenia. This increase would help neuroplasticity with improvement of mental functions in such patients (Konradi & Heckers, 2001 and Lieberman et al, 2005). The results of these human studies open the way in front of many researchers in this field to do long-term studies with various SGAs to study the possible beneficial regional neuroplasticity-induced by these drugs.

Similarly, many clinical studies reported, in a confident manner, that neurotropins such as (NGF) and BDNF are decreased in schizophrenic patients of different age groups. These neurotropins have a crucial role in neuroplasticity and protection against apoptosis that is a part of pathogenesis of this disease (Buckley et al, 2007).

Quetiapine actually stimulates BDNF expression and reduces the immobilization that accompany the exposure to stress in rat hippocampus (Xu et al, 2002) as well as significantly increases BDNF and fibroblast growth factor 2
(FGF-2) mRNA in rat’s hippocampus, neocortex either these rats are stressed or not (Angelucci et al, 2005 & Park et al, 2006 and Poepl et al, 2014).

Recently, Gamma-aminobutyric acid (GABA) is thought to play a role in the pathophysiology of schizophrenia. There is a strong evidence that schizophrenic patients will get a lot of therapeutic benefit when treated with drugs that result in an increase in the expression of postsynaptic GABA\_A receptors. This increase will be considered as a compensatory mechanism to the deficit in GABA release from DLPFC neurons with an increase in the efficacy of GABA neurotransmission at DLPFC. This will be of great therapeutic benefit in schizophrenic patients as drugs acting on GABA receptors would augment the neuroplasticity modifications associated with improving memory with marked improvement of negative symptoms (Mirnics et al, 2001). Studies are focused on the action of both typical and atypical antipsychotics on GABA concentration in basal ganglia and the anterior singulate nucleus of schizophrenic patients. The results were very promising as regards the increase in GABA concentration in these areas of patients measured in a proton magnetic resonance spectroscopy study with its proposed beneficial effects in modification of impaired memory and enhancement of neuroplasticity in such disease. However, more studies are needed to support the GABAergic therapeutic action of SGAs especially as there is a strategy to develop drugs acting on GABAergic system to treat psychiatric diseases as depression and bipolar disorders (Tayoshi et al, 2009 and Vashchinkina et al, 2014).

A lot of clinical studies summarized the main pathological changes of schizophrenia to be due to dopaminergic overstimulation which can lead to cell death (Ben-Shachar et al, 2004), glutamate excitotoxicity (Deutsch et al, 2001), GABA dysfunction (Farber et al, 2003), impaired anti-apoptotic signaling (Datta et

Currently, there is a strong recommendation to design many clinical trials, whose aim is to prove in a definite manner the possible improvement of neuroplasticity and the expected reversal of the associated pathological changes that affect the brain of schizophrenic patients by SGAs when used in the treatment of schizophrenic patients. These trials will help a lot to reach curative drugs to this mental disease (Melissa et al, 2010 and Doan et al, 2015).

In conclusion, there is a strong evidence that atypical antipsychotics possess an important role in neuroplasticity and neuroprotection when administered to schizophrenic patients. The results of many studies pointed to this obvious neuroprotective effect and to the capacity of neurogenesis of SGAs. This will open a new era to investigate new drugs, especially GABAergic drugs, in an attempt to reach a complete cure of chronic neuropsychiatric diseases such as schizophrenia. This target can be achieved if studies can develop new drugs that depend mainly in their mechanism of action on both neuroplasticity and regeneration of abnormal neuronal circuits so they can replenish the brain neurotropic factors. These drugs could successfully be used in treatment of recurrent episodes of schizophrenic patients.

These impressing studies will help to announce very soon in the future the appearance of new new drugs to treat this psychotic illness. Further advances in psychopharmacology may include an array that properly investigate the neuroplastic mechanism of action of these new drugs to reach a complete brain repair that is needed in such destructive mental diseases.
References


